In this latest episode of ASTCT Talks, Dr. Rahul Banerjee, MD, FACP, sits down with Dr. Urvi A. Shah, MD, to discuss CAR-T vs bsAbs among academic audiences, bispecific antibodies (in particular commercially available teclistamab), future cycles of teclistamab, infections in published trials of bsAbs in myeloma and more.

About Dr. Rahul Banerjee, MD, FACP

Dr. Banerjee, MD, FACP, (@RahulBanerjeeMD) is an Assistant Professor in the Division of Medical Oncology at the University of Washington and at the Fred Hutchinson Cancer Center. Prior to moving to Seattle, he completed his hematology/oncology fellowship and advanced fellowship in BMT/CAR-T therapy at the University of California San Francisco. His clinical interests are in multiple myeloma, AL amyloidosis, and CAR-T therapy. His research interests are in toxicity management, digital health, and the patient experience.

About Dr. Urvi A. Shah, MD

Dr. Urvi Shah, MD, (@UrviShahMD) is an Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center (MSK) and Assistant Professor of Medicine at Weill Cornell Medicine. She completed fellowships in hematology/oncology at Montefiore Medical Center, and in cancer immunotherapy by MSK and the Parker Institute for Cancer Immunotherapy in New York. She is board certified in Internal Medicine, Hematology and Medical Oncology.  Her clinical practice includes all plasma cell disorders and her research interests include immune therapies and modifiable risk factors (diet, metabolism, and the microbiome). She opened the first pilot nutrition trial in plasma cell disorders to date (NUTRIVENTION; NCT04920084) in 2021 that completed enrollment. She has 3 other NUTRIVENTION/immune therapy investigator-initiated trials (NCT05640843, NCT04497961, NCT04174196) currently enrolling. Dr. Shah has been supported by career development awards from the National Cancer Institute Paul Calabresi K12, International Myeloma Society and American Society of Hematology Scholar Award.